Literature DB >> 16107892

CDK2 catalytic activity and loss of nuclear tethering of retinoblastoma protein in childhood acute lymphoblastic leukemia.

N M R Schmitz1, K Leibundgut, A Hirt.   

Abstract

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. During cell cycle progression from the mid- to late G1 phase, mammalian cells traverse the restriction point, a transition from mitogen dependence to mitogen independence, regulated by retinoblastoma protein (Rb). Different cyclin-dependent kinases (CDKs) sequentially phosphorylate and inactivate Rb, which is associated by a change in Rb's nuclear affinity and activation of E2F transcription. Here, we show by in vitro kinase assays that ALL extracts contained CDK2 catalytic activity. When liberation of Rb from cell nuclei was tested by immune precipitation of differential cell extractions and Western blot analysis, little Rb was associated with the nuclear compartment. Together with the immunocytochemical analysis at a single cell level that Rb was phosphorylated at serine 612 and threonine 821, sites known to be phosphorylated by CDK2, the data indicated the presence of CDK2 catalytic activity and loss of Rb's nuclear affinity in ALL cells. We conclude that most ALL cells reside at or beyond the restriction point. This could explain the resistance of ALL cells to differentiation induction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107892     DOI: 10.1038/sj.leu.2403900

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  9 in total

1.  Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia.

Authors:  Nicole M R Schmitz; Andreas Hirt; Markus Aebi; Kurt Leibundgut
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

2.  miR-638 regulates differentiation and proliferation in leukemic cells by targeting cyclin-dependent kinase 2.

Authors:  Yi Lin; Dengju Li; Qing Liang; Shangqing Liu; Xuelan Zuo; Lin Li; Xuemei Sun; Wenxin Li; Mingxiong Guo; Zan Huang
Journal:  J Biol Chem       Date:  2014-12-01       Impact factor: 5.157

3.  Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.

Authors:  Giulio Rastelli; Andrew Anighoro; Martina Chripkova; Laura Carrassa; Massimo Broggini
Journal:  Cell Cycle       Date:  2014-06-09       Impact factor: 4.534

4.  An integrated approach to inferring gene-disease associations in humans.

Authors:  Predrag Radivojac; Kang Peng; Wyatt T Clark; Brandon J Peters; Amrita Mohan; Sean M Boyle; Sean D Mooney
Journal:  Proteins       Date:  2008-08-15

5.  Molecular basis for viral selective replication in cancer cells: activation of CDK2 by adenovirus-induced cyclin E.

Authors:  Pei-Hsin Cheng; Xiao-Mei Rao; Kelly M McMasters; Heshan Sam Zhou
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

6.  Drug targets for cell cycle dysregulators in leukemogenesis: in silico docking studies.

Authors:  Archana Jayaraman; Kaiser Jamil
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

7.  Regulatory Network and Prognostic Effect Investigation of PIP4K2A in Leukemia and Solid Cancers.

Authors:  Shouyue Zhang; Zhaozhi Li; Xinyu Yan; Li Bao; Yun Deng; Feier Zeng; Peiqi Wang; Jianhui Zhu; Dandan Yin; Fei Liao; Xueyan Zhou; Duyu Zhang; Xuyang Xia; Hong Wang; Xue Yang; Wanhua Zhang; Hu Gao; Wei Zhang; Li Yang; Qianqian Hou; Heng Xu; Yan Zhang; Yang Shu; Yuelan Wang
Journal:  Front Genet       Date:  2019-01-15       Impact factor: 4.599

8.  Differentiation resistance through altered retinoblastoma protein function in acute lymphoblastic leukemia: in silico modeling of the deregulations in the G1/S restriction point pathway.

Authors:  Eleftherios Ouzounoglou; Dimitra Dionysiou; Georgios S Stamatakos
Journal:  BMC Syst Biol       Date:  2016-03-01

9.  Effects of CB2 and TRPV1 receptors' stimulation in pediatric acute T-lymphoblastic leukemia.

Authors:  Francesca Punzo; Iolanda Manzo; Chiara Tortora; Elvira Pota; Velia D' Angelo; Giulia Bellini; Alessandra Di Paola; Federica Verace; Fiorina Casale; Francesca Rossi
Journal:  Oncotarget       Date:  2018-04-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.